DOCSLIB.ORG

Generic Formulary - 2015 S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Generic Formulary - 2015 S GENERIC FORMULARY - 2015 S. N. Composition Strength Form VMS_code NEW VMS 1. Anaesthetics 1 Atropine 0.6 mg / ml Inj G01019 2 Benzocaine 20% Gel G01026 3 Bupivacaine 25mg/10ml Inj G01010 4 Bupivacaine 50mg/10ml Inj G01011 5 Bupivacaine in Dextrose 5% +7.5% Inj G01012 6 Desflurane 250 ml Inhalation G01027 7 Dexmedetomidine 100mg/ml Inj G01028 8 Diazepam 5 mg/ml Inj G01020 9 Doxapram 4 mg/ml Inj G01032 10 Ethyl Chloride 1% Spray G01013 11 Glycopyrroolate 0.2 mg/ml Inj G01029 12 Halothane Inhalation Inhalation G01002 13 Isoflurane Inhalation Inhalation G01003 14 Ketamine 50mg/ml Inj G01005 15 Ketamine 10 mg / ml Inj G01004 16 Lignocaine and Adrenaline 1% + 1:200,000 Inj G01017 17 Lignocaine and Adrenaline 2% + 1:200,000 Inj G01018 18 Lignocaine and Dextrose 5%+7.5% Inj G01016 19 Lignocaine 2% Gel G01014 20 Lignocaine 2,5% Gel G01033 21 Lignocaine 1% INJ G01034 22 Lignocaine 2% INJ G01015 23 Lignocaine 5% GEL G01035 24 Midazolam Injection 1 mg / ml Inj G01021 25 Midazolam Injection 5mg/ml Inj G01022 26 Nitrous Oxide Inhalation Inhalation G01006 27 Oxygen Inhalation Inhalation G01007 28 Propofol Injection 10 mg / ml Inj G01025 29 Sevoflurane 250MG Inhalation G01024 30 Thiopentone Injection I.P 0.5G 0.5G Inj G01008 31 Thiopentone Injection I.P 0.5G 1 G Inj G01009 32 Xylocaine spray 10% 10% Spray G01030 2. A n a l g e s i c s , A n t i p y r e t i c s , N o n s t e ro i d a l Anti-inflammatory Medicines, Medicines used to treat 33 AceclofenacRheumatoid 100mg Disorders. Tab G02046 34 Aceclofenac 200mg Tab G02047 35 Aceclofenac + Paracetamol+ Rabiprazole 100mg+325mg+ Tab G02048 Sodium 10mg 36 Aceclofenac+ Paracetamol + Serratiopeptidase 100mg+325mg+ Tab G02049 10mg 37 Aceclofenac+ Paracetamol + Serratiopeptidase 100mg+325mg+ Tab G02050 15mg 38 Aceclofenac + Rabiprazole Sodium 200mg+20mg Tab G02051 39 Aceclofenac+Paracetamol 100mg+500mg Tab G02052 40 Aceclofenac+Paracetamol 100mg+325mg Tab G02053 41 Aceclofenac+Paracetamol 100mg+650mg Tab G02054 42 Aceclofenac +Thiocolchicoside 100mg+4mg Tab G02055 43 Aceclofenac +Thiocolchicoside 200mg+8mg Tab G02056 44 5-Aminosalicylic Acid 400 mg tab G17037 45 Allopurinol 100 mg tab G02015 46 Calcipotriol 0.005% tube G02057 47 Chlorzoxazone, Diclofenac And Paracetamol 250 mg+50 tab G02037 mg+325 mg 48 Colchicine 0.5 mg tab G02016 49 Diacerein 50mg Cap G02023 50 Diacerein + glucosamin 50mg+750mg Tab G02058 Page 1 of 42 S. N. Composition Strength Form VMS_code NEW VMS 51 Diclofenac And Paracetamol 50Mg+ 325Mg tab G02059 52 Diclofenac +Metaxalone 50mg+400mg Tab G02060 53 Diclofenac +Serratiopeptidase 50mg+10mg Tab G02061 54 Diclofenac Pottasium+ Thiocholchiside 50mg+8mg Tab G02062 55 Diclofenac 25 mg / ml inj G02004 56 Diclofenac 50MG Tab G02002 57 Diclofenac 75mg Tab G02043 58 Diclofenac 100MG Tab G02042 59 Diclofenac 150MG Tab G02063 60 Diclofenac 1%w/v oint G02025 61 Diclofenac Potassium And Tizanidine 50 mg+2 mg tab G02039 62 Diclofenac Potassium And Tizanidine 100mg+2mg tab G02064 63 Diclofenac Potassium And Tizanidine 75mg+2mg tab G02065 64 Diclofenac +Paracetamol +Serrtiopeptidase 50mg+325mg+1 Tab G02066 0mg 65 Etodolac 400mg Tab G02067 66 Etodolac 600mg Tab G02068 67 Etodolac +Paracetamol 400mg+500mg Tab G02069 68 Etorocoxib +Thiocolchicoside 60mg+4mg Tab G02070 69 Etorocoxib +Thiocolchicoside 60mg+8mg Tab G02071 70 Etoricoxib 90 mg tab G02026 71 Etoricoxib 60MG tab G02072 72 Etoricoxib 120MG tab G02073 73 Fentanyl 50 ug/ml inj G02022 74 flupiritine maleate 100mg cap G02074 75 FLUTRIPTINE And THIOCOLCHICOSIDE 100MG + 8MG Tab G02075 76 Ibuprofen and Paracetamol 400MG+ 325MG tab G02034 77 Ibuprofen and Paracetamol 400MG+ 500MG tab G02036 78 Ibuprofen 200 mg tab G02005 79 Ibuprofen 400mg tab G02006 80 Indomethacin 25mg Tab G02076 81 Indomethacin 75mg Tab G02077 82 Chlorzoxazone +diclofenac +Paracetamol 500mg+50mg+3 Tab G02078 25mg 83 Leflunomide 10mg tab G02021 84 Leflunomide 20 mg tab G02027 85 Lornoxicam 8 mg tab G02028 86 Loraxicam +Thiocolchicoside 4mg+4mg Tab G02079 87 Mefenamic Acid 500mg Cap G02029 88 Mefenamic Acid 250mg Cap G02080 89 Mefanamic+ Thanexamic Acid 250mg+500mg Cap G02081 90 Morphine 10mg/ml inj G02010 91 Morphine 15mg/ml inj G02030 92 Morphine 10mg tab G02011 93 Naproxen 25mg Tab G02082 94 Naproxen 250mg tab G02083 95 Naproxen 375mg Tab G02084 96 Naproxen 500mg Tab G02085 97 Naproxen 750mg Tab G02086 98 Nimesulide And Paracetamol 100mg+ 500mg tab G02038 99 Nimesulide And Tizanidine 200mg+ 2mg tab G02040 100 Nimesulide Tablet 100 mg tab G02031 101 Paracetamol and Dextropropoxyphen 325 mg+ 65 mg tab G02087 102 Paracetamol And Tramadol 325mg+ 37.5mg tab G02041 103 Paracetamol 150mg/ml Inj G02007 104 Paracetamol 125mg/5ml Syp G02008 105 Paracetamol 500 mg tab G02009 Page 2 of 42 S. N. Composition Strength Form VMS_code NEW VMS 106 Paracetamol 650mg Tab G02088 107 Pentazocine 30 mg / ml inj G02013 108 Pentazocine 25 mg tab G02012 109 Pethidine Injection 50 mg / ml inj G02014 110 Piroxicam 20mg Tab G02089 111 Serratiopeptidase 10mg Tab G02090 112 Sufentanil 50 mcg/ml inj G02033 113 Sulphasalazine 500 mg tab G02018 114 Sulphasalazine 1000mg Tab G02091 115 Tramadol 50 mg/ ml inj G02032 116 Tramadol 100mg INJ G02092 117 Tramadol 50MG TAB G02093 118 Zaltoprofen 80mg Tab G02094 3. Antiallergics and Medicines used in Anaphylaxis 119 Adrenaline Bitartrate 1 mg / ml Inj G03001 120 Azelastine 0.10% Nasal Spray G03011 121 Cetirizine 5mg/5ml Syrup G03013 122 Cetirizine 10mg Tab G03009 123 Chlorpheniramine 4 mg Tab G03002 124 Cyproheptadine 4mg Tab G03014 125 Cyproheptadine 2mg Tab G03022 126 Cyproheptadine 2mg/5ml Syrup G03023 127 Cyproheptadine 1mg/ml Syrup G03024 128 Dexchlorpheniramine 2mg/5ml Syrup G03003 129 Dexchlorpheniramine .5mg/5ml Syrup G03025 130 Fexofenadine 120mg Tab G03007 131 Fexofenadine 180mg Tab G03008 132 Hydroxyzine 10mg/5ml Syrup G03018 133 Hydroxyzine 10mg Tab G03016 134 Hydroxyzine 25mg Tab G03017 135 Levocetirizine 5 mg Tab G03019 136 Loratadine 10MG Tab G03020 137 Pheniramine 22.75 mg / ml Inj G03006 138 Pheniramine 25 mg Tab G03021 139 Promethazine 25MG/ML Inj G17019 140 Promethazine 5mg/5ml Syrup G17018 141 Promethazine 10mg Tab G17016 4. Antidotes and Other Substances used in Poisonings 142 Snake Venom Antiserum I.P. (Polyvalent) 10 ml Inj G04002 Lyophiliz ed 143 Lyophilyzed Polyvalent Serum Snake Venom 10ML Inj G04023 Antiserum 144 Activated Charcoal Powder G04001 145 Activated Charcoal 500MG Tab G04014 146 Calcium Gluconate 100 mg / ml Inj G04003 147 Deferasirox 100 mg Tab G04015 148 Deferasirox 400 mg Tab G04016 149 Deferasirox 250 mg Tab G04017 150 Deferasirox 500 mg Tab G04018 151 Desferrioxamine 500mg Inj G04004 152 Desferrioxamine 50 mg / ml Inj G04024 153 Disulfiram 250mg Tab G04025 154 Disulfiram 500mg Tab G04026 155 Flumazenil 0.1 mg / ml Inj G04006 156 Methylthioninium Chloride (Methylene blue) 10 mg / ml Inj G04007 Page 3 of 42 S. N. Composition Strength Form VMS_code NEW VMS 157 Naloxone 0.4 mg / ml Inj G04008 158 Penicillamine 250 mg Tab G04009 159 Penicillamine 150mg Tab G04027 160 Pralidoxime Chloride 25 mg/ml Inj G04010 161 Sodium Nitrite 30 mg/ml Inj G04011 162 Oral Iron Chelating Agent 250 mg Tab G04013 163 Flumazenil 2 mg Inj G04019 164 Naloxone 200mcg/ml Inj G04020 165 Naloxone 400mcg/ml Inj G04021 166 Sodium Thiosulphate 250mg/ml Inj G04022 5. Anticonvulsants/Antiepileptics 167 Carbamazepine 100 mg Tab G05001 168 Carbamazepine 200mg Tab G05002 169 Carbamazepine 300mg Tab G05028 170 Carbamazepine 400 mg Tab G05015 171 Carbamazepine 100 mg / 5 ml Syrup G05003 172 Divalproex sodium 250mg Tab G05029 173 Divalproex sodium 500mg Tab G05030 174 Divalproex sodium 750mg Tab G05031 175 Divalproex sodium 1000mg Tab G05032 176 Eslicarbazepine 400mg Tab G05033 177 Gabapentin And Methylcobalamin 300+ 500mcg Tab G05025 178 Gabapentin Tablet 300 mg Tab G05016 179 Gabapentin Tablet 100mg Tab G05034 180 Gabapentin + Nortriptyline HCL 400mg+10mg Tab G05035 181 Magnesium valproate 200mg caps/Tab G05036 182 Magnesium Sulphate 500mg/ml Inj G05004 183 Magnesium Sulphate 50%W/V OINT G05037 184 Methylcobalamin And Pregabalin 750mcg+ 75mg Cap G05027 185 LACOSAMIDE 100mg Tab G05038 186 LACOSAMIDE 10mg/ml INJ G05039 187 Levetiracetam 100mg/ml Syrup G05040 188 Levetiracetam 100mg Tab G05041 189 Levetiracetam 250mg Tab G05042 190 Levetiracetam 500mg Tab G05018 191 Levetiracetam 750mg Tab G05043 192 Oxcarbazepine 150 mg Tab G05019 193 Oxcarbazepine 300mg Tab G05020 194 Oxcarbazepine 250mg Tab G05021 195 pyridostigmine 30mg Tab G05044 196 pyridostigmine 60mg Tab G20005 197 pyridostigmine 90mg Tab G05045 198 pyridostigmine 5mg/ml INJ G20006 199 pyridostigmine 2mg/ml INJ G05046 200 Phenobarbitone 30 mg Tab G05005 201 Phenobarbitone 60mg Tab G05006 202 Phenobarbitone 200mg /ml Inj G05007 203 Phenytoin 50mg Tab G05008 204 Phenytoin 100 mg Tab G05009 205 Phenytoin 125mg/5ml Susp G05010 206 Phenytoin 50mg/ml Inj G05011 207 Pramipexole .5mg Tab G05047 208 Pramipexole 1mg Tab G05048 209 Promidone 50mg tab/caps G05049 210 Promidone 250mg tab/caps G05050 211 Sodium Valproate 200 mg Tab G05012 212 Sodium Valproate 500mg Tab G05013 Page 4 of 42 S. N. Composition Strength Form VMS_code NEW VMS 213 Sodium Valproate 300mg Tab G05051 214 Sodium Valproate 200 mg / 5 ml Susp G05014 215 Sodium Valproate 100mg/ml INJ G05022 216 Sodium Valproate + Valporic Acid 135mg+58mg Tab G05052 217 Sodium Valproate + Valporic Acid 200mg+87mg Tab G05053 218 Sodium Valproate + Valporic Acid 333mg+145mg Tab G05054 219 Topiramate 25 mg Tab G05023 220 Topiramate 50mg Tab G05055 221 Topiramate 100mg Tab G05056 222 Zonisamide 100 mg Tab G05024 223 Zonisamide 50mg Tab G05057 224 Zonisamide 25mg Tab G05058
Load more

Recommended publications
  • UNASYN® (Ampicillin Sodium/Sulbactam Sodium)
    NDA 50-608/S-029 Page 3 UNASYN® (ampicillin sodium/sulbactam sodium) PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of UNASYN® and other antibacterial drugs, UNASYN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION UNASYN is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration. Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]- 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate and has a molecular weight of 371.39. Its chemical formula is C16H18N3NaO4S. The structural formula is: COONa O CH3 N CH O 3 NH S NH2 Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R)-3,3-dimethyl-7-oxo-4-thia­ 1-azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide. Its chemical formula is C8H10NNaO5S with a molecular weight of 255.22. The structural formula is: NDA 50-608/S-029 Page 4 COONa CH3 O N CH3 S O O UNASYN, ampicillin sodium/sulbactam sodium parenteral combination, is available as a white to off-white dry powder for reconstitution. UNASYN dry powder is freely soluble in aqueous diluents to yield pale yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL.
    [Show full text]
  • Estrogen Metabolism in the Human Estrogen Metabolism in the Human
    ENE PURRE: ESTROGEN METABOLISM IN THE HUMAN ESTROGEN METABOLISM IN THE HUMAN A THESIS BY ENE PURRE SUBMITTED TO THE FACULTY OF GRADUATE STUDIES AND RESEARCH IN PARTIAL FULFILMENT FOR THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE McGILL UNIVERSITY MONTREAL, CANADA. DEPARTMENT OF EXPERIMENTAL MEDICINE AUGUST 1965 TABLE OF CONTENTS Page No. I INTRODUCTION A. Early history and isolation of the e strogens 2 B. Metabolism of the estrogens 4 1. Biogenesis 4 2. Metabolism 6 3. Degradation 14 4. Conjugation 15 c. Altered states of estrogen metabolism 18 Purpose of the Investigation II MATERIALS AND METHODS 25 Materials I Radioactive compounds 25 II Non-radioactive compounds 25 Ill Enzymes 26 IV Reagents 26 Methods I Purification of radioactive steroids 30 II Preparation of non-radioactive standards 31 III Spectophotometric and f1uorimetric readings 31 IV Counting methods 32 V Enzyme assays 33 VI Injections 33 VII Collection of urine 34 VIII Hydrolysis and extraction of urines 34 IX Assay of estrone, estradiol-17 f.:' and estriol 36 X Attempts at separa ting ring 011( keto1s 3 7 XI Assay of ring D..: ketols in the urine 39 XII Recrysta1lization studies 40 ---------------···---- TABLE OF CONTENTS (cont.) Page No._ Ill RESULTS Section I - Studies with control subjects and those with myocardial infarction 41 Section II- A. Recovery of 16~-hydroxyestrone and 16-ketoestradiol-17~ from toluene/ propylene glycol system 50 B. Pre 1 imi nary study on urinary ring De>< ketols 51 c. Urinary ring D<K ke to 1 s in nonnal males 53 D. Studies of the excretion and metabolism of eight estrogen metabolites from urine 59 IV DISCUSSION 71 SUMMARY 87 BIBLIOGRAPHY 89 • LIST OF FIGURES Figure No.
    [Show full text]
  • AUGMENTIN® (Amoxicillin/Clavulanate Potassium) Tablets
    NDA 50-564/S-051 Page 3 AG:AL16 PRESCRIBING INFORMATION AUGMENTIN® (amoxicillin/clavulanate potassium) Tablets To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN (amoxicillin/clavulanate potassium) and other antibacterial drugs, AUGMENTIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION AUGMENTIN is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. The amoxicillin molecular formula is C16H19N3O5S•3H2O, and the molecular weight is 419.46. Chemically, amoxicillin is (2S,5R,6R)-6-[(R)-(-)-2-Amino-2-(p- hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus. It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C8H8KNO5, and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (Z)- (2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate, and may be represented structurally as: Inactive Ingredients: Colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide.
    [Show full text]
  • The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones
    Placenlal Function and Fetal Nutrition, edited by Frederick C. Battaglia, Nestle Nutrition Workshop Series. Vol. 39. Nestec Ltd.. Vevey/Lippincott-Raven Publishers. Philadelphia. © 1997. The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones Lise Cedard U. 361 INSERM, Maternite Baudelocque, 121 Boulevard de Port-Royal Paris, France The placenta is classically considered to be a source of hormones that play an important role in the establishment and maintenance of pregnancy. Because of its hemochorial structure, the human placenta produces hormones and easily secretes them into the maternal circulation. They include steroid hormones, such as estrogens and progesterone, and protein hormones, the most important of which are the chori- onic gonadotrophins (hCG), discovered in 1927. During the period from 1960 to 1980, the concept of a fetoplacental unit (1) with a complementary role for the fetus in steroid production offered a new approach to steroid metabolism, and since then new proteins and neuropeptides have been discovered (2,3). However, the lack of innervation of placental tissue highlights the importance of understanding neuroen- docrine regulation of placental physiology. Sophisticated culture methods enabling the study of biologic phenomena occurring during transformation of cytotrophoblast cells into a syncytiotrophoblast (4) have been combined with electron microscopy and histochemistry. Possibilities offered by molecular biology, including in situ hybridization and molecular cloning studies,
    [Show full text]
  • Common Formulary of Generic Drugs for Medical Store Organisation, CGHS, Dr
    Common Formulary Of Generic Drugs For Medical Store Organisation, CGHS, Dr. R.M.L Hospital, Safdarjung Hospital And Lady Harding Medical College & Kalawati Saran Children Hospital-2011 With VMS Nos (Vocabulary of Medical Stores) Common Formulary Of Generic Drugs For Medical Store Organisation, CGHS, Dr. R.M.L Hospital, Safdarjung Hospital And Lady Harding Medical College & Kalawati Saran Children Hospital With Effect From 23-05-2011 SlNO VMS No Nomenclature Type of Strength Medicine 1. Anaesthetics 1.1 General Anaesthetics and Oxygen 1 G01002 Halothane Inhalation 250ml (Halothane with Inhalation Inhalation vaporizer) 2 G01003 Isoflurane Inhalation Inhalation Inhalation 3 G01004 Ketamine Hydrochloride 10 mg / ml Injection 10 mg / ml 10ml 4 G01005 Ketamine Hydrochloride 10 mg / ml Injection 50mg/ml 10ml 5 G01006 Nitrous Oxide Inhalation Inhalation 6 G01007 Oxygen Inhalation Inhalation Inhalation 7 G01008 Thiopentone Sodium Injection 0.5 g powder 8 G01009 Thiopentone Sodium Injection 1g powder 9 G01024 Sevoflurane Inhalation 250ml Bott Inhalation Inhalation 10 G01025 Propofol Injection 1% 11 G01027 Desflurane 250 ml Inhalation 250 ml 1.2 Local Anaesthetics 12 G01010 Bupivacaine Hydrochloride Injection 0.25% 13 G01011 Bupivacaine Hydrochloride Injection 0.50% 14 G01012 Bupivacaine in Dextrose Injection 0.5% +7.5% 15 G01013 Ethyl Chloride Spray 1% 16 G01014 Lignocaine Hcl Gel 2-5% 17 G01015 Lignocaine Hcl Injection 2% 18 G01016 Lignocaine Hydrochloride and Dextrose Injection 5% +7.5% 19 G01017 Lignocaine Hydrochloride and Adrenaline Injection
    [Show full text]
  • New Zealand Data Sheet 1
    New Zealand Data Sheet 1. PRODUCT NAME Ibiamox® 250mg Powder for injection Ibiamox® 500mg Powder for injection Ibiamox® 1000mg Powder for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION The amoxicillin is present as the sodium salt in Ibiamox (1059mg of amoxicillin sodium is equivalent to approximately 1000mg of amoxicillin). Ibiamox 250mg Powder for injection contains 250mg amoxicillin. Ibiamox 500mg Powder for injection contains 500mg amoxicillin. Ibiamox 1000mg Powder for injection contains 1000mg amoxicillin. 3. PHARMACEUTICAL FORM Ibiamox vials: white to cream powder packed in clear glass vials for reconstitution. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Amoxicillin should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. Amoxicillin is indicated for treatment of infections in adults and children at the following sites, when caused by sensitive organisms: • upper respiratory tract including ear, nose and throat infections, e.g. tonsillitis, sinusitis, otitis media • lower respiratory tract, e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia • gastrointestinal tract, e.g. typhoid fever • genito-urinary tract, e.g. cystitis, urethritis, pyelonephritis, bacteriuria in pregnancy, gonorrhoea, septic abortion, puerperal sepsis • other infections including Borreliosis (Borrelia burgdorferi) (Lyme Disease) • prophylaxis of endocarditis: amoxicillin may be used for the prevention of bacteraemia associated with the development of endocarditis (see table in section 4.2 Dose and method of administration) • Skin and soft tissue infections (SSSIs). Susceptibility to amoxicillin will vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary (see section 5.1 Pharmacodynamic properties). 1 | Page 4.2.
    [Show full text]
  • Vocabulary of Medical Store(VMS) of Generic Drugs Sl VMS Code ITEM DESCRIPTION (NOMENCLATURE + STRENGTH + DOSAGE FORM + SPECIFICATION) PACK SIZE No
    Vocabulary of Medical Store(VMS) of Generic Drugs Sl VMS Code ITEM DESCRIPTION (NOMENCLATURE + STRENGTH + DOSAGE FORM + SPECIFICATION) PACK SIZE No. 1. ANAESTHETICS 1 G01019 ATROPINE INJECTION I.P 0.6 MG / ML 1 ML AMP 2 G01026 BENZOCAINE GEL 20% 15 GM TUBE 3 G01010 BUPIVACAINE INJECTION I.P 25MG/10ML 20 ML VIAL 4 G01011 BUPIVACAINE INJECTION I.P 50MG/10ML 20 ML VIAL 5 G01012 BUPIVACAINE IN DEXTROSE INJECTION 0.5% +7.5% 20 ML VIAL 6 G01027 DESFLURANE INHALATION 250ML BOTTLE 7 G01028 DEXMEDETOMIDINE INJECTION 100MG/ML 2 ML VIAL 8 G01020 DIAZEPAM INJECTION I.P 5 MG / ML 2 ML AMP 9 G01032 DOXAPRAM INJECTION 4 MG / ML 2 ML VIAL 10 G01013 ETHYL CHLORIDE SPRAY 1% 100ML CONTAINER 11 G01029 GLYCOPYRROOLATE INJECTION 0.2 MG/ML 1 ML AMP 12 G01002 HALOTHANE (WITH VAPORIZER) INHALATION 250ML BOTTLE 13 G01003 ISOFLURANE INHALATION 100ML BOTTLE 14 G01005 KETAMINE INJECTION I.P 50MG/ML 2 ML VIAL 15 G01004 KETAMINE INJECTION I.P 10 MG / ML 10 ML VIAL 16 G01017 LIGNOCAINE AND ADRENALINE INJECTION I.P 1% + 1:200,000 30 ML VIAL 17 G01018 LIGNOCAINE AND ADRENALINE INJECTION I.P 2% + 1:200,000 20 ML VIAL 18 G01016 LIGNOCAINE AND DEXTROSE INJECTION I.P 5% +7.5% 2 ML AMP 19 G01014 LIGNOCAINE GEL I.P 2% 30 GM TUBE 20 G01015 LIGNOCAINE INJECTION I.P 2% 30 ML VIAL 21 G01035 LIGNOCAINE GEL 5% 20GM TUBE 22 G01021 MIDAZOLAM INJECTION 1 MG / ML 5 ML VIAL 23 G01022 MIDAZOLAM INJECTION 5MG/ML 1 ML AMP 24 G01006 NITROUS OXIDE INHALATION 100 ML BOTTLE 25 G01007 OXYGEN INHALATION 100ML BOTTLE 26 G01025 PROPOFOL INJECTION I.P 10MG/ML 20 ML VIAL 27 G01024 SEVOFLURANE INHALATION 250 ML BOTTLE 28 G01008 THIOPENTONE INJECTION I.P 0.5G VIAL 29 G01009 THIOPENTONE INJECTION I.P 1G VIAL 30 G01030 XYLOCAINE SPRAY 10% 50 ML BOTTLE 2.
    [Show full text]
  • Unconjugated Estradiol, Estriol and Total Estriol in Maternal Peripheral
    Endocrinol. Japon. 1983, 30 (2), 155-162 Unconjugated Estradiol, Estriol and Total Estriol in Maternal Peripheral Vein, Cord Vein, and Cord Artery Serum at Delivery in Pregnancies with Intrauterine Growth Retardation. CHIKAYUKI, TAYAMA, SHUNZO ICHIMARU, MASAHARU ITO, MICHIO NAKAYANA, MASAO MAEYAMA AND ISAO MIYAKAWA Department of Obstetrics and Gynecology, Kumamoto University Medical School, Kumamoto 860 and *Department of Obstetricts and Gynecology, Miyazaki Medical College, Miyazaki Abstract The levels of unconjugated estradiol(E2), estriol (E3) and total (conjugated plus unconjugated) E3 in maternal vein serum during labor, cord vein serum, and cord artery serum were measured in normal singleton and twin pregnanceis with appropriate for dates babies (AFD) and with light for dates babies (LFD). The mean level of total E3 in the maternal vein serum in singleton pregnancy was significantlylower in the LFD group than in the AFD group, but no differenceswere seen in the mean levels of unconjugated E2 or E3 between the groups. The concentration of uncon- jugated E2 in the maternal vein serum was significantlyhigher in the twin group with a large placenta than in the singleton group with a small placenta, while the concentration of total E3 in the case of twin pregnancy with LFD was lower than that in singleton pregnancy with AFD but not significantly. No difference in the concentration of total E3 was observed between the cord vein serum and cord artery serum. The present data suggest that the total E3 level in maternal vein serum may be used in evaluating fetal states such as intrauterinegrowth retardation. In pregnancy complicated by intrauterine conjugated E2 and E3 into the maternal and growth retardationwith or without symptoms fetal circulation and to determine the total of maternal disease,such as toxemia of pre- (conjugated plus unconjugated) E3 in the gnancy or hypertension,not only the urinary maternal and fetal blood.
    [Show full text]
  • Thesis.Pdf (432.0Kb)
    Some hormonal factors in the etiology of endometrial cancer Elisabete Weiderpass Stockholm 1999 Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden Some hormonal factors in the etiology of endometrial cancer Elisabete Weiderpass Stockholm 1999 2 To all women who took part in these studies 3 ABSTRACT The main purpose of this dissertation was to study the impact of some hormone-related factors in the etiology of endometrial neoplasms, i.e. hormone replacement therapy, use of oral contraceptives, serum levels of 20 different organochlorine substances, and polymorphisms in the estrogen receptor α (ER) gene. We conducted two population-based case-control studies among post-menopausal women. In the first one, 789 women with a reported diagnosis of primary endometrial cancer and 3368 age-frequency-matched control women were enrolled from all over Sweden. These women answered a questionnaire on use of oral contraceptives and hormone replacement therapy, among other questions. We used unconditional logistic regression to calculate odds ratios (OR) as estimates of relative risks. We found a duration-dependent increase in the relative risk of endometrial cancer both among women who used orally administered estriol, 1-2 mg/day (multivariate OR following 5 or more years of use: 3.0; 95% confidence interval [CI] 2.0-4.4) and medium-potency estrogens without addition of progestins (multivariate odds ratio following 5 or more years of use: 6.7; 95% CI 4.3-10.5), compared to women who never used these substances. Following combined estrogen-progestin use, the association was considerably weaker (multivariate odds ratio following 5 or more years of use: 1.6; 95% CI 1.1-2.4) than for estrogens without progestins, and the increased relative risk was confined to women using cyclic regimens (i.e.
    [Show full text]
  • Department of Health & Human Services Nda 50-757/S
    Public Health Service DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville, MD 20857 NDA 50-757/S-011 PRIOR APPROVAL SUPPLEMENT TAP Pharmaceutical Products Inc. Attention: John R. Lieberman, Ph.D Regulatory Advisor 675 North Field Drive Lake Forest, IL 60045 Dear Dr. Lieberman: Please refer to your supplemental new drug application dated January 31, 2005, received February 1, 2005, submitted under section 505(b)(1) of the Federal Food, Drug and Cosmetic Act for PREVPAC® (lansoprazole/amoxicillin/clarithromycin). This supplemental new drug application provides for the following revisions to the package insert (additions are double underlined and deletions are strikethrough): 1. The TRIMOX® (amoxicillin, USP) subsection of the DESCRIPTION section was revised to read: Amoxicillin, USP, (2S,5R,6R)-6-[( R)-(-)-2-Amino-2-(p-hydroxyphenyl) acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate is a semi-synthetic penicillin antibiotic, an analogue of ampicillin, with a broad spectrum of bactericidal activity against many gram –positive and gram-negative microorganisms. Chemically it is (2S,5R,6R)-6-[( R)-(-)-2-Amino- 2-(p-hydroxyphenyl) acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid trihydrate. Amoxicllin capsules are intended for oral administration. 2. The Amoxicillin: subsection of the CLINICAL PHARMACOLOGY section was revised to read: Most of the amoxicillin is excreted unchanged in the urine; its excretion can be delayed by concurrent administration of probenicid. Amoxicillin is not highly protein bound. In blood serum, amoxicillin is approximately 20% protein bound as compared to 60% for penicillin G.
    [Show full text]
  • Study Protocol Drug Substance Ceftazidime-Avibactam Study Code D4280C00015 Edition Number 2 Date 07 March 2017 Approximately 70 Study Centres Are Planned
    .9/L"H(A"L .-4*.LDF KL09E:92L Qe2ne"V`J'+n ')PX-$-9'T/Z!J:Z ^f)kn L),n Z *6Z7LIneE",Pn Z [,n ZC!+Z Z @4 +'@ ( ,@ +.) 4@)8'5!+51@ 6 :@ .,51.''@52 '@6.@; '9 5@ 4 5=@ 5.'7 ' 6=@/ ) .& +6!4@ +@" =@.@5 > *@ +@ ; 5 )@<-@ #;,@ #,@.) + 5 .,@< 5@)51.+! ?.(@ .)0 2@< 5@ 32./+)@ +@ (1,@2.)@ ).+64@6.@'44@5 +@ = 24@ .@ @<$6@ .)0( 6@ ,6 .)!, '@ +5!.+4@% %4@ <97A9=L V`P'I&' n bD),P[;?<,ni,*,In PPD AE="5"L"B">%L5L )!# B(E"L >";?"B"6DE+I"L PPD \,n \f*ln-).Pn PP n D n n PP n,Z4,P?!I)Wn PPD n n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e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT) PROTOCOL SYNOPSIS A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam when given in combination with metronidazole, compared with meropenem, in children from 3 months to less than 18 years of age with complicated intra-abdominal infections (cIAIs) International Co-ordinating Investigator PPD , MD PPD United States Study site(s) and number of patients planned A sufficient number of patients are to be randomised 3:1 for 80 patients to complete at least 72 hours (3 full days, ie, 9 doses) of study treatment (ie, evaluable patients; at least 60 patients in the ceftazidime and avibactam [CAZ-AVI] plus metronidazole group and at least 20 patients in the meropenem group).
    [Show full text]
  • UNASYN® (Ampicillin Sodium/Sulbactam Sodium)
    UNASYN® (ampicillin sodium/sulbactam sodium) To reduce the development of drug-resistant bacteria and maintain the effectiveness of UNASYN® and other antibacterial drugs, UNASYN should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION UNASYN is an injectable antibacterial combination consisting of the semisynthetic antibacterial ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration. Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]-3, 3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylate and has a molecular weight of 371.39. Its chemical formula is C16H18N3NaO4S. The structural formula is: COONa O CH 3 N CH O 3 NH S NH 2 1 Reference ID: 4683820 Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R)-3,3-dimethyl-7-oxo-4-thia- 1-azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide. Its chemical formula is C8H10NNaO5S with a molecular weight of 255.22. The structural formula is: COONa CH 3 O N CH 3 S O O UNASYN, ampicillin sodium/sulbactam sodium parenteral combination, is available as a white to off-white dry powder for reconstitution. UNASYN dry powder is freely soluble in aqueous diluents to yield pale yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL. The pH of the solutions is between 8.0 and 10.0.
    [Show full text]